Gemcitabine could suppress phospho-Akt expression, and the migration and invasion of pancreatic ductal adenocarcinoma cells.[82] The combination of GM-CSF and gemcitabine induced a high level of immune activation and T-cell proliferation in patients with stage I or II pancreatic adenocarcinomas.[83] The downregulation of sorafenib on the Akt signaling pathway has been reported in a wide range of research studies on human diseases.[84,85] However, the application of these drugs for the management of sepsis-induced immunosuppression has not been reported till now. Here, CSF2 is linked to pancreatic ductal adenocarcinoma.